🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This phase Ib/II trial studies the best dose of glembatumumab vedotin when ...
Status
Withdrawn
Location
Multiple Locations
Start Date
2018-04-20
Trial ID
NCT03326258
Treatments Being Tested
Celldex endeavors to make investigational products available to patients wi...
Status
No Longer Available
Location
Multiple Locations
Start Date
TBD
Trial ID
NCT03067935
Treatments Being Tested
The main purpose of this study is to see whether CDX-011 (glembatumumab ved...
Status
Completed
Location
Alabama Oncology
Start Date
2013-11
Trial ID
NCT01997333
Treatments Being Tested
This phase II trial studies how well glembatumumab vedotin works in treatin...
Status
Completed
Location
Children's Hospital of Alabama
Start Date
2016-02-16
Trial ID
NCT02487979
Treatments Being Tested
This phase II trial studies how well glembatumumab vedotin works in treatin...
Status
Completed
Location
Mayo Clinic Hospital
Start Date
2015-09-16
Trial ID
NCT02363283
Treatments Being Tested
Patients with advanced or metastatic, gpNMB-expressing Squamous Cell Carcin...
Status
Terminated
Location
University of Miami Hospital
Start Date
2016-04-10
Trial ID
NCT02713828
Treatments Being Tested
This is a single arm, pilot study assessing safety/feasibility and efficacy...
Status
Withdrawn
Location
Multiple Locations
Start Date
2018-05-01
Trial ID
NCT03473691
Treatments Being Tested
The main purpose of this study is to see whether CDX-011 is effective in tr...
Status
Completed
Location
The University of Alabama at Birmingham Comprehensive Cancer Center
Start Date
2010-07
Trial ID
NCT01156753
Treatments Being Tested
This study will examine the effectiveness and safety of glembatumumab vedot...
Status
Terminated
Location
The Angeles Clinic and Research Institute
Start Date
2014-11
Trial ID
NCT02302339